Ian Davis, Professor of Medicine at Monash University and Eastern Health and Director and Chair of ANZUP, shared a post on X:
“Two opinions that to my surprise are either unpopular or not widely held:
- The control arm of a randomised trial should be best standard of care.
- A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.”
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on by Ian Davis, adding:
“Agree 100%. These shouldn’t be controversial. These are just common sense.”
More posts featuring Ian Davis and Bishal Gyawali on OncoDaily.